$0.318
-0.060 (-18.79%)終値時点
HEPA のニュース
HEPA のイベント
Hepion Pharmaceuticals Licenses Novel Biomarker Assay for Liver Cancer from Cirna Diagnostics
Hepion Pharmaceuticals has in-licensed from Cirna Diagnostics, a novel biomarker assay that detects mutant circulating tumor RNA to facilitate early diagnosis of hepatocellular carcinoma in high-risk patients. Most cases of liver cancer are HCC, and HCC is the sixth most common cancer worldwide, with a high mortality-to incidence ratio that makes it the third deadliest cancer globally. The in-licensing agreement advances Hepion's strategic evolution and complements its recently acquired methylated DNA test for early detection of liver cancer, the mSEPT9 PCR-based assay. Hepion's new strategic focus is advancing clinically proven liquid biopsy tests to aid in the early diagnosis and surveillance of HCC and potentially other solid tumor types in the near future, and to this end Hepion has also secured rights to potentially extend Cirna's ctRNA platform for other indications as the technology matures. The ctRNA license for HCC, and extension rights, augment Hepion's growing pipeline as the company prepares its mSEPT9 PCR-based assay for commercialization. The Company believes both assays will fulfill a major unmet need, as current HCC surveillance methods miss up to 75% of early-stage cancers. The ctRNA biomarker assay is a blood-based test that reads the RNA signals shed by tumors into circulation. It detects cancer-specific mutant RNA variants in blood, offering a next-generation approach to liquid biopsy. Unlike DNA-based approaches, ctRNA captures actively expressed tumor signatures, providing earlier detection and improved specificity across both surveillance and early detection use cases. The platform has been validated for HCC across several independent cohorts, with standardized RNA extraction and a repertoire of HCC-specific variants being integrated into a single multiparametric blood test.
Hepion Pharmaceuticals completes application to OTCQB
Hepion Pharmaceuticals has completed the process of transitioning to the OTCQB Venture Market. The Company's common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.
Hepion Pharmaceuticals appoints Kaouthar Lbiati as interim CEO
Hepion Pharmaceuticals announced that Kaouthar Lbiati has been named as interim CEO, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Lbiati has served on Hepion's Board of Directors since June 2022 and brings over 15 years of global leadership experience in both biotech and large pharmaceutical companies. She also serves on the board of Theralase Technologies
Hepion announces receipt of delisting notification from Nasdaq
Hepion Pharmaceuticals announced that on May 9, the company received written notice from the Office of General Counsel of The Nasdaq Stock Market indicating that the Nasdaq Hearings Panel has determined to delist the company's shares from Nasdaq due to the company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the company is a public shell. The Notice indicated that trading in the company's shares of common stock on Nasdaq will be suspended effective at the open of trading on Tuesday, May 13. Upon suspension of the trading of its common stock on Nasdaq, the company expects that its common stock will be quoted under its existing symbol "HEPA" on the OTC Markets Group.
Hepion Pharmaceuticals enters binding LOI with New Day Diagnostics
Hepion Pharmaceuticals announced that it has entered into a binding letter of intent, LOI, with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex, helicobacter pylori and hepatocellular carcinoma. The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time. The diagnostic tests covered under the LOI represent a combined addressable market exceeding $15 billion. John Brancaccio, Executive Chairman and Interim Chief Executive Officer of Hepion expressed his enthusiasm about this licensing opportunity: "The CE marked tests provide Hepion with the ability to generate near term revenues in European Union countries by leveraging the existing distributor network relationships that New Day Diagnostics has established. We are excited by this opportunity and look forward to working with New Day to maximize value."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。